NBIF sought urgent government intervention to address regulatory delays at home and high tariffs abroad that hinder the ₹40,000 crore biostimulant sector.
The industry, with 5,000+ SMEs, faces tariffs of 15–28% and non-tariff barriers like efficacy trials and residue tests in key export markets.
Lack of mutual recognition agreements with blocs like the EU and ASEAN worsens export hurdles.